Ultragenyx Pharmaceutical Inc. buy JPMorgan Chase & Co.
Start price
27.02.24
/
50%
€49.60
Target price
27.02.25
€81.12
Performance (%)
-20.97%
Price
16.05.24
€39.20
Summary
This prediction is currently active. The price of Ultragenyx Pharmaceutical Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -20.97%. This prediction currently runs until 27.02.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Ultragenyx Pharmaceutical Inc. | 1.031% | 1.031% |
iShares Core DAX® | -0.051% | 4.829% |
iShares Nasdaq 100 | 1.659% | 2.417% |
iShares Nikkei 225® | 0.658% | -2.173% |
iShares S&P 500 | 0.964% | 2.547% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $84.00 to $88.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat